Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Bone Health Technologies announces positive Topline Results from Groundbreaking Pivotal Trial of Non-pharmacological Treatment for Osteopenia
Bone Health Technologies (BHT), a leading innovator of technologies for improving bone health, has announced […]
Medical Mutual Finalizes Acquisition of Reserve National Insurance Company
On Dec. 1, 2022, Medical Mutual closed on the acquisition of Reserve National Insurance Company, […]
Net Health PointRight's RADAR® Care Management Solution Launches Predictive Modeling Feature
New predictive models tapping the power of machine learning (ML) have been integrated into Net […]
Ionis Announces European Medicines Agency Accepts Marketing Authorization Application of Tofersen to Treat Rare, Genetic form of ALS
Ionis Pharmaceuticals has announced that the European Medicines Agency (EMA) has accepted the marketing authorization application […]
Syndax Announces U.S. FDA Breakthrough Therapy Designation Granted for Patients with Relapsed or Refractory KMT2A- Rearranged (MLLr) Acute Leukemia
Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced […]
Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis
Lynk Pharmaceuticals, an innovative clinical-stage company, announced that it has dosed the first patient in […]
Carle Health Partners with Health Catalyst to Achieve Data-Informed Improvement
Health Catalyst, a leading provider of data and analytics technology and services to healthcare organizations, […]
NRx Pharmaceuticals Appoints Carrie M. Carretta as Senior Vice President of Clinical Development and Medical Affairs
NRx Pharmaceuticals, a clinical-stage central nervous system (CNS) biopharmaceutical company, has announced the appointment of […]
Alnylam Announces Approval of AMVUTTRA® in Brazil for the Treatment of Transtirretina-Mediated Hereditary Amyloidosis in Adults
Alnylam Pharmaceuticals, a leading RNAi therapy company, has announced that the National Health Surveillance Agency […]
Istesso Announces FDA Fast Track and Orphan Drug Designation for MBS2320
Istesso Limited, the immunometabolism drug discovery and development company, has announced that the US Food […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more